The translation of basic science research into novel diagnostic and therapeutic tools for prostate cancer has been severely limited by a dearth of independently-funded investigators with the requisite clinical, analytical, and technical skills necessary to confront this formidable intellectual challenge. Our overall strategy for recruiting and training highly-talented individuals for this task involves the creation of a formal, multidisciplinary program combining intensive research training, graduate level courses, and regularly scheduled seminars addressing both the clinical and pathologic aspects of prostate cancer. Most importantly, we will provide frequent and regular opportunities for cross-fertilization between clinical and basic scientists working in this area. We will use the SPORE Career Development funds to establish a formal training program for clinically- and scientifically-trained post-doctoral fellows to hone their research skills in the area of prostate cancer. We will focus on post-doctoral trainees, because they represent the group most likely to continue in this area as independent investigators. Although we plan to train both pre-doctoral and post-doctoral investigators in our SPORE laboratories, the Career Development funds will be used exclusively for those post-doctoral investigators who are likely to develop independent careers translating basic molecular and cellular biology of the prostate into novel diagnostic and therapeutic tools. We will fund at least four SPORE Career Development Fellows per year using a combination of SPORE and institutional funds. We envision three sources for top-quality candidates for these positions, all of which will be advertised nationally i) those individuals of high merit who have recently completed clinical training in Urology and are interested in acquiring the basic-science research skills necessary to become an independently-funded investigator; ii) those individuals of high merit who have recently completed clinical training in Pathology and are interested in acquiring the basic-science research skills necessary to become and independently-funded investigator; iii) Ph.D. investigators who have recently completed their theses in a basic science laboratory and who have strong research interests in areas related to normal and/or neoplastic prostate biology. In addition to supporting up to four SPORE Career Development Fellows per year, we will use the Career Development funds to recruit and nurture one or more junior faculty members of highest merit in the area of translational prostate cancer research. We will provide salary support for up to five years and will protect these physician-scientists from clinical responsibilities during this time. We plan to seek for this position an individual with solid scientific training, though not necessarily in the area of prostate cancer, since the SPORE RFA has recognized a paucity of funded investigators in this area. We will use the SPORE funds and the overall SPORE environment to reinforce the orientation of this individual's independent research program towards translational aspects of prostate cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA058204-01
Application #
3796284
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Olar, Adriana; He, Dandan; Florentin, Diego et al. (2014) Biological correlates of prostate cancer perineural invasion diameter. Hum Pathol 45:1365-9
Olar, Adriana; He, Dandan; Florentin, Diego et al. (2014) Biologic correlates and significance of axonogenesis in prostate cancer. Hum Pathol 45:1358-64
Sonpavde, Guru; Wang, Mingjun; Peterson, Leif E et al. (2014) HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Invest New Drugs 32:235-242
Nakka, Manjula; Agoulnik, Irina U; Weigel, Nancy L (2013) Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. Int J Biochem Cell Biol 45:763-72
Ding, Yi; He, Dandan; Florentin, Diego et al. (2013) Semaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer. Clin Cancer Res 19:6101-11
Feng, Shu; Dakhova, Olga; Creighton, Chad J et al. (2013) Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res 73:2551-62
Yang, Feng; Zhang, Yongyou; Ressler, Steven J et al. (2013) FGFR1 is essential for prostate cancer progression and metastasis. Cancer Res 73:3716-24
Yang, Guang; Goltsov, Alexei A; Ren, Chengzhen et al. (2012) Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer. Mol Cancer Res 10:218-29
Sonpavde, Guru; Thompson, Timothy C; Jain, Rajul K et al. (2011) GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res 17:7174-82
Wang, Jianghua; Cai, Yi; Shao, Long-Jiang et al. (2011) Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4. Cancer Res 71:1325-33

Showing the most recent 10 out of 262 publications